Focal Segmental Glomerulosclerosis clinical trials at University of California Health
3 research studies open to eligible people
Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
open to eligible people ages 16-75
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact…
at UCSF
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
open to eligible people ages 1-65
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
at UC Davis
Nephrotic Syndrome Study Network
open to eligible people ages up to 80 years
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD)…
at UCLA UCSF
Our lead scientists for Focal Segmental Glomerulosclerosis research studies include Sharon Adler, MD Paul Brakeman, MD, PhD.
Last updated: